Capital Fund Management S.A. I Mab Transaction History

Capital Fund Management S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $548,755 - $1.22 Million	-66,355 Reduced 51.5%	62,492 $706,000
Q1 2022 May 12, 2022	BUY	$12.54 - $46.93 $1.35 Million - $5.04 Million	107,383 Added 500.29%	128,847 $2.09 Million
Q4 2021 Feb 10, 2022	BUY	$45.28 - $74.5 $971,889 - $1.6 Million	21,464 New	21,464 $1.02 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.